Silexion Therapeutics discovers synergistic efficacy between SIL-204 and first-line chemotherapy for pancreatic cancer

From GlobeNewswire: 2025-01-15 16:01:00

Silexion Therapeutics Corp. announced new preclinical results showing the synergistic efficacy of its siRNA candidate, SIL-204, with components of first-line chemotherapy for pancreatic cancer. SIL-204 demonstrated significant synergistic activity with 5-fluorouracil, irinotecan, and gemcitabine in human pancreatic tumor cell lines with KRAS G12D mutations. These findings suggest the potential of SIL-204 to enhance standard chemotherapy treatments for pancreatic cancer and other KRAS-mutated cancers. Silexion plans to initiate toxicology studies with SIL-204 soon and advance it to Phase 2/3 trials, focusing on locally advanced pancreatic cancer. The company also aims to study SIL-204 in colorectal cancer models.



Read more at GlobeNewswire: Silexion Therapeutics Announces Additional Promising